WO2012037547A3 - Méthodes et compositions utilisées pour inhiber l'autophagie dans le traitement de la fibrose - Google Patents

Méthodes et compositions utilisées pour inhiber l'autophagie dans le traitement de la fibrose Download PDF

Info

Publication number
WO2012037547A3
WO2012037547A3 PCT/US2011/052128 US2011052128W WO2012037547A3 WO 2012037547 A3 WO2012037547 A3 WO 2012037547A3 US 2011052128 W US2011052128 W US 2011052128W WO 2012037547 A3 WO2012037547 A3 WO 2012037547A3
Authority
WO
WIPO (PCT)
Prior art keywords
fibrosis
treatment
methods
compositions
inhibiting autophagy
Prior art date
Application number
PCT/US2011/052128
Other languages
English (en)
Other versions
WO2012037547A2 (fr
Inventor
Scott L. Friedman
Zahra Ghiassi-Nejad
Virginia Hernandez-Gea
Original Assignee
Mount Sinai School Of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mount Sinai School Of Medicine filed Critical Mount Sinai School Of Medicine
Priority to EP11826075.1A priority Critical patent/EP2616082A2/fr
Publication of WO2012037547A2 publication Critical patent/WO2012037547A2/fr
Publication of WO2012037547A3 publication Critical patent/WO2012037547A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Cette invention concerne des compositions et des méthodes utilisées dans le traitement de la fibrose. Cette invention concerne plus particulièrement des inhibiteurs d'autophagie et leurs méthodes d'utilisation dans le traitement de la fibrose du foie, des poumons, des reins et d'autres tissus, et l'inhibition de l'activation des cellules de Kupffer.
PCT/US2011/052128 2010-09-17 2011-09-19 Méthodes et compositions utilisées pour inhiber l'autophagie dans le traitement de la fibrose WO2012037547A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP11826075.1A EP2616082A2 (fr) 2010-09-17 2011-09-19 Méthodes et compositions utilisées pour inhiber l'autophagie dans le traitement de la fibrose

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38407610P 2010-09-17 2010-09-17
US61/384,076 2010-09-17

Publications (2)

Publication Number Publication Date
WO2012037547A2 WO2012037547A2 (fr) 2012-03-22
WO2012037547A3 true WO2012037547A3 (fr) 2012-06-28

Family

ID=45832287

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/052128 WO2012037547A2 (fr) 2010-09-17 2011-09-19 Méthodes et compositions utilisées pour inhiber l'autophagie dans le traitement de la fibrose

Country Status (2)

Country Link
EP (1) EP2616082A2 (fr)
WO (1) WO2012037547A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102013110608A1 (de) * 2013-09-26 2015-03-26 Florian Lang Substanz zur Hemmung von Gewebskalzifizierung, Gewebsfibrosierung und altersassoziierten Erkrankungen
CN103948601A (zh) * 2014-05-06 2014-07-30 山东大学 3-甲基腺嘌呤在制备治疗动脉粥样硬化及其相关疾病的药物中的应用
GB201512609D0 (en) * 2015-07-17 2015-08-26 Royal Veterinary College The Methods
US10618939B2 (en) * 2016-06-29 2020-04-14 The Hong Kong Polytechnic University Hydrocarbon-stapled polypeptides for enhancement of endosome-lysosomal degradation
EP3620164A1 (fr) * 2018-09-05 2020-03-11 Genoscience Pharma SAS 2,4 diamino-quinoline substituée en tant que nouveau médicament destiné à la fibrose, l'autophagie et des maladies liées aux cathepsines b (ctsb), l (ctsl) et d (ctsd)
CN115151561A (zh) * 2019-09-25 2022-10-04 前沿药品公司 靶向自噬缀合物和方法
CN113134004A (zh) * 2021-03-29 2021-07-20 中国医学科学院医学生物学研究所 一种3-甲基腺嘌呤在制备预防铜绿假单胞菌诱导的急性肺炎药物中的应用
CN115960884B (zh) * 2022-03-19 2024-03-12 三峡大学 靶向活化型肝星状细胞的核酸适配体APT-Tan的筛选方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030203867A1 (en) * 2000-06-30 2003-10-30 Greenberg Arnold H. NIP3 family of proteins
WO2004035782A2 (fr) * 2002-10-17 2004-04-29 Artemis Pharmaceuticals Gmbh Silençage genique induit par sirna chez les animaux transgeniques
US20040087016A1 (en) * 2000-05-12 2004-05-06 University Of Utah Research Foundation Compositions and methods for cell dedifferentiation and tissue regeneration
US20050009053A1 (en) * 2003-04-25 2005-01-13 Sebastian Boecker Fragmentation-based methods and systems for de novo sequencing
US20080194504A1 (en) * 2004-02-06 2008-08-14 Advanced Bionutrition Corporation Rna-Mediated Interference to Control Disease in Terrestrial and Aquaculture Animals
WO2009065090A2 (fr) * 2007-11-14 2009-05-22 University Of Hawaii Compositions pharmaceutiques pour le traitement d'affections sensibles à une inhibition du protéasome
US20100190749A1 (en) * 2008-11-03 2010-07-29 Pingda Ren Benzoxazole kinase inhibitors and methods of use

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040087016A1 (en) * 2000-05-12 2004-05-06 University Of Utah Research Foundation Compositions and methods for cell dedifferentiation and tissue regeneration
US20030203867A1 (en) * 2000-06-30 2003-10-30 Greenberg Arnold H. NIP3 family of proteins
WO2004035782A2 (fr) * 2002-10-17 2004-04-29 Artemis Pharmaceuticals Gmbh Silençage genique induit par sirna chez les animaux transgeniques
US20050009053A1 (en) * 2003-04-25 2005-01-13 Sebastian Boecker Fragmentation-based methods and systems for de novo sequencing
US20080194504A1 (en) * 2004-02-06 2008-08-14 Advanced Bionutrition Corporation Rna-Mediated Interference to Control Disease in Terrestrial and Aquaculture Animals
WO2009065090A2 (fr) * 2007-11-14 2009-05-22 University Of Hawaii Compositions pharmaceutiques pour le traitement d'affections sensibles à une inhibition du protéasome
US20100190749A1 (en) * 2008-11-03 2010-07-29 Pingda Ren Benzoxazole kinase inhibitors and methods of use

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK 7 April 2005 (2005-04-07), retrieved from http://www.ncbi.nlm.nih.gov/nuccore/BV482162 accession no. V482162 *
DATABASE GENBANK retrieved from http://www.ncbi.nlm.nih.gov/nucgss/FH102951 accession no. H102951 *
LUCIANI ET AL.: "Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition.", NATURE CELL BIOLOGY, vol. 12, no. 9, September 2010 (2010-09-01), pages 863 - 875 *

Also Published As

Publication number Publication date
WO2012037547A2 (fr) 2012-03-22
EP2616082A2 (fr) 2013-07-24

Similar Documents

Publication Publication Date Title
WO2012037547A3 (fr) Méthodes et compositions utilisées pour inhiber l'autophagie dans le traitement de la fibrose
WO2011032169A3 (fr) Compositions et formulations pharmaceutiques comprenant des inhibiteurs du domaine d'homologie à la pleckstrine et leurs méthodes d'utilisation
WO2012103059A3 (fr) Inhibiteurs de bcl-2/bcl-xl et méthodes thérapeutiques les utilisant
WO2012024620A3 (fr) Inhibiteurs de l'autotaxine et leurs utilisations
MX2019010602A (es) Inhibidores de cdk.
IL222484A0 (en) Arginase inhibitor compounds, compositions comprising the same and uses thereof
WO2011002808A8 (fr) Inhibiteurs de la protéase du vhc et leurs utilisations
WO2011031896A3 (fr) Inhibiteurs de pi3 kinase et leurs utilisations
WO2012158843A3 (fr) Inhibiteurs de kinase
MY181898A (en) Heterocyclic compounds and uses thereof
WO2010120757A3 (fr) Régénération de tissus sans transplantation de cellules
WO2012087288A3 (fr) Compositions de sels métalliques
WO2008124660A3 (fr) Procédés et compositions pour le traitement du cancer
WO2012065019A3 (fr) Inhibiteurs pyridopyrimidinone de p13k alpha
WO2011113060A3 (fr) Composés antiviraux et procédés d'utilisation de ceux-ci
WO2010132882A3 (fr) Compositions sublinguales de dexmédétomidine et leurs procédés d'utilisation
WO2009129267A3 (fr) Inhibiteurs de petites molécules du domaine d'homologie de la pleckstrine, et leurs méthodes d'utilisation
PH12014501273A1 (en) Intranasal dexmedetomidine compositions and methods of use thereof
WO2012040389A3 (fr) Inhibiteurs bicycliques substitués du virus de l'hépatite c
WO2012122383A3 (fr) Inhibiteurs de pi3 kinase et leurs utilisations
WO2010033977A3 (fr) Composes multiheteroaryles servant d'inhibiteurs de la h-pgds, ainsi que leur utilisation dans le traitement des maladies induites par la prostaglandine d2
WO2013003298A3 (fr) Inhibiteurs de pde10
WO2009114703A3 (fr) Thérapie combinée pour le traitement d'un cancer
WO2013023084A3 (fr) Procédés et compositions pour l'inhibition de la croissance et/ou de la prolifération de cellules tumorales activées par myc
IL223865A0 (en) Calcium salts of dihydrooroorotate dehydrogenase inhibitors, compositions comprising the same and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11826075

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011826075

Country of ref document: EP